SADC Platform
Multiple (Anti-Drug Antibodies, Gene Therapy Neutralizing Antibodies, Autoimmune Conditions)
Key Facts
About Ablevia
Ablevia is a Vienna-based, preclinical-stage biotechnology company pioneering a novel therapeutic approach for the selective removal of pathogenic antibodies. Its core technology, SADC, utilizes peptide-based compounds designed to bind and neutralize specific, harmful antibodies—such as those causing autoimmune disorders or neutralizing biologic drugs and gene therapy vectors—while sparing the protective immune repertoire. Founded by an MD and a business operations expert, the company operates as a research and development entity seeking partnerships to advance its platform into clinical applications for rare diseases and conditions with high unmet need. Ablevia represents a potential paradigm shift in managing antibody-mediated conditions by moving from broad immunosuppression to targeted antibody clearance.
View full company profile